secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2026-03-20T23:59:59+00:00
Accession:  0001493152-26-011829
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lixte Biotechnology raises CEO base salary to $360,000 effective Jan 1, 2026
----------------------------------------------------------------------------

- CEO Geordan Pursglove's annual base salary increased from $240,000 to $360,000.
- Increase effective retroactively to January 1, 2026; initial payment includes catch-up amount.
- Amendment approved by Compensation Committee and Board of Directors on March 18, 2026.
- Employee may elect to receive salary in cash or restricted shares based on closing price.
- Amendment filed as Exhibit 10.1 to Form 8-K dated March 18, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315226011829/0001493152-26-011829-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315226011829/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-011829

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer